As New Jersey’s only NCI-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey together with
RWJBarnabas Health
, provides patients access to the most advanced treatment options including complex surgical procedures, sophisticated radiation therapy techniques, innovative clinical trials, immunotherapy, and precision medicine.
|
|
|
Rutgers Cancer Institute Offers Clinical Trial Examining Potential Treatment for COVID-19
|
|
|
|
Rutgers Cancer Institute of New Jersey, a National Cancer Institute-designated Comprehensive Cancer Center, is offering a clinical trial as a potential treatment for patients diagnosed with the coronavirus (COVID-19). At present clinical management includes infection prevention, control measures and supportive care. Researchers at Rutgers Cancer Institute are exploring if the antibiotic azithromycin combined with a malaria drug known as hydroxychloroquine is better than hydroxychloroquine alone for treatment of patients with COVID-19. The trial, which is being offered at Rutgers Cancer Institute, Robert Wood Johnson University Hospital in New Brunswick, and University Hospital in Newark, is not limited to cancer patients. As an NCI-designated Comprehensive Cancer Center, Rutgers Cancer Institute has the expertise and infrastructure to conduct this important clinical trial.
|
|
COVID-19: What Cancer Patients Need to Know
|
|
|
|
At Rutgers Cancer Institute of New Jersey, we are taking extra precautions to provide the safest environment possible for our patients, visitors and staff amid COVID-19 (coronavirus) concerns. Along with instituting changes to our visiting guidelines and implementing screening measures in accordance with guidance from the Centers for Disease Control and Prevention, we aim to share the most current information on how COVID-19 impacts cancer patients.
Andrew M. Evens, DO, MSc, FACP
, associate director for Clinical Services and director, Lymphoma Program, Rutgers Cancer Institute; medical director, Oncology Service Line, RWJBarnabas Health; and professor of medicine, Rutgers Robert Wood Johnson Medical School, shares
more.
|
|
Exploring the Impact of Autophagy on Stress Response Pathways in Cancer
|
|
|
|
Research from investigators at Rutgers Cancer Institute of New Jersey shows that a cellular process known as autophagy promotes survival in mouse models by suppressing oxidative stress and a tumor suppressor known as p53. Rutgers Cancer Institute of New Jersey Deputy Director, Chief Scientific Officer, and Associate Director for Basic Research
Eileen P. White, PhD
, who is a distinguished professor of molecular biology and biochemistry in the School of Arts and Sciences at Rutgers University, is the senior author of the work published in the March 19 online edition of
Genes & Development (DOI: 10.1101/gad.335570.119).
Learn more
|
|
Check out the Latest Edition of
Cancer Connection
Magazine
|
|
|
|
The latest digital edition of
Cancer Connection
magazine is now available, highlighting the journeys of cancer survivors with extraordinary courage and the latest in cancer research advances. You’ll learn about unique cancer support services and incredible members of our community who are making a difference in supporting the expert care provided by Rutgers Cancer Institute and RWJBarnabas Health.
Learn more
|
|
|
|
|
|
|
